We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Effort Under Way in U.S. to Discourage Pay-for-Delay
Effort Under Way in U.S. to Discourage Pay-for-Delay
December 9, 2011
First-filer generic drugmakers that win patent challenges in U.S. district court, or are not sued by the brand company after filing an abbreviated new drug application, could be forced to share their 180-day market exclusivity under a new bill.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor